INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

ClinicalTrials.gov ID: NCT02977780

Public ClinicalTrials.gov record NCT02977780. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 8, 2026, 6:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (arm is currently closed to accrual) * CC115 (arm is currently closed to accrual) * QBS10072S

Study identification

NCT ID: NCT02977780
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: David Reardon, MD; Other
Enrollment: 460 participants

Conditions and interventions

Conditions

Glioblastoma

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 8, 2017
Primary completion: Jan 31, 2028
Completion: Apr 29, 2028
Last update posted: Aug 18, 2026

2017 – 2028

United States locations

U.S. sites: 12
U.S. states: 10
U.S. cities: 10

Facility	City	State	ZIP	Site status
University of Alabama at Birmingham	Birmingham	Alabama	35294	Active, not recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
Dana Farber Cancer Institute	Boston	Massachusetts	02115	Recruiting
Mayo Clinic	Rochester	Minnesota	55905	Active, not recruiting
Columbia University Medical Center	New York	New York	10032	Active, not recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
Cleveland Clinic	Cleveland	Ohio	44195	Active, not recruiting
University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania	15232	Recruiting
Lifespan / Rhode Island Hospital	Providence	Rhode Island	02903	Active, not recruiting
UT MD Anderson Cancer Center	Houston	Texas	77030	Completed
Huntsman Cancer Institute	Salt Lake City	Utah	84112	Active, not recruiting
University of Virginia Health System	Charlottesville	Virginia	22908	Completed

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02977780, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 18, 2026 · Synced Sep 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02977780 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →